Since coming to the Wake Forest Baptist Medical Center in 1998, Edward Levine, M.D., has developed a myriad of interests – cancers of the stomach, liver, breast and esophagus among them – but none intrigue him more than peritoneal mesothelioma. “It’s a fascinating disease,” he said.
Levine is the professor of surgery and chief of the Surgical Oncology Service at Wake Forest. Hes considered an international expert on the combined treatment of surgery and heated chemotherapy for peritoneal cancers and has appeared several times on the Castle Connelly list of America’s Top Doctors for Cancer.
The Comprehensive Cancer Center within Wake Forest’s Medical Center has more than 120 clinicians specializing in some aspect of cancer care and is the only National Cancer Institute-designated facility in western North Carolina.
Levine, who has published more than 150 works, is also the head of the Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) program.
Along with his teaching and administrative duties at Wake Forest, he also serves on numerous committees with the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Get help connecting with Dr. Levine and find the treatment that's best for you.
When 2011 began, Levine was the principal investigator for 25 clinical/translational protocols, receiving grants from the National Cancer Alliance (NCA), various industries and the Comprehensive Cancer Center for his research involving genomic analysis of solid tumors.
His clinical interests revolve around general surgical oncology, including gastrointestinal malignancies. He also has focused on melanoma, breast cancer and varied peritoneal malignancies.
Levine began his career in Chicago at the Rosalind Franklin University of Medicine and Science. He completed his residency at the nearby Michael Reese Hospital. He did his fellowship in surgical oncology at the University of Illinois before joining the staff at Louisiana State University.
When it comes to waging the war against peritoneal mesothelioma – especially when compared to other cancers – Edward A. Levine, M.D., sometimes feels like he’s going to battle with one hand tied behind his back.
Unfortunately, the tools we have to fight mesothelioma now are crude. It’s a very complicated disease, and we’re fighting a complex disease with blunt weapons. That’s frustrating – when you realize the limitations of what you can do with what is available.
Levine is the director at large of the Comprehensive Cancer Center and professor of Surgical Oncology at Wake Forest University Baptist Medical Center. He has been at the school since 1998, long enough to be part of the significant changes in the treatment of the disease, yet knowing that even more dramatic ones are on the way.
“We know a lot more about this disease than we did 10 years ago. When it was absolutely uniform, we didn’t understand the sub-types of it,” he said. “The molecular underpinnings of this disease are only now being sorted out in detail. I’m pretty sure in the next 10 years, it’s going to bear more fruit in terms of selected molecular targets, personalized therapies. Ten years ago, it was just on the chalkboard.”
Levine also treats patients with breast cancer, esophageal cancer, peritoneal carcinomatosis, gastrointestinal tumors, and melanoma. Nowhere does he wage such an uphill battle as he does with mesothelioma, a relatively rare but devastating cancer. He doesn’t see enough specialists who can treat it effectively. And he sees far too much erroneous information about it, information that is long outdated in a changing environment.
“Be careful what you find on the Internet [about mesothelioma therapy]. A lot of it is unfiltered. The information may or may not be correct,” he said. “Some of it is outstanding advice, and some of it is pure bunk. You don’t know.”
Too many times he has heard about patients who gave up without even exploring their options for treatment. There is hope now that wasn’t there a decade ago, or even a few years ago, he said.
“To have a patient read something that is totally wrong, then get completely discouraged, just go home and die – when maybe there was treatment available – that’s so frustrating,” he said. “It shouldn’t be that way.”
Although he is based in the area of Winston-Salem, North Carolina, Levine treats patients from all over the country. Some come to his hospital, but for many he works through outside oncologists or physicians in the cities where the patients live. It’s a long-distance doctor/patient relationship.
I have a referral base of 30 states. If you can’t work that way, you probably have no business treating this disease. If you work in New York or L.A., the population is big enough to not do that. Most of us work with other centers.
And while the number of candidates for surgery has grown significantly in recent years, he said, determining who can benefit most from that surgery is not always clear cut.
“So much depends on the clinical situation and the tumor biology,” he said. “Someone has an aggressive operation and lives – that doesn’t mean an aggressive operation is right for you.”
Levine’s commitment to research through the years has left him both frustrated by the pace of progress in finding a cure for mesothelioma, yet invigorated by the potential of finding one.
“It [mesothelioma] is a fascinating disease,” Levine said. “Most of these patients, through no fault of their own, find themselves in a very tough, clinical situation. The truth is – we’re able to help most of them. To bring some science to bear, and try and make the treatment better for everyone, is a good thing. As big a tragedy as it is for any one patient to have this disease, an even bigger tragedy would be to not learn from it.”
View our resources for patients and familiesGet Help Today